| (Values in U.S. Thousands) | Jan, 2026 | Jan, 2026 | Jan, 2026 | Jan, 2026 | Jan, 2026 |
| Sales | 0 | 0 | 0 | 0 | 0 |
| Sales Growth | unch | unch | unch | unch | unch |
| Net Income | 0 | 0 | 0 | 0 | 0 |
| Net Income Growth | unch | unch | unch | unch | unch |
Biosensors Intl Grp (BSNRF)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Biosensors International Group Ltd is a limited liability company incorporated in Bermuda. The Company is an investment holding company. The business activities of the Company are those of investment holding and licensing of proprietary medical technology. The Company develops, manufacture and markets medical devices for interventional cardiology and critical care procedures. The Group's business are organized into various segments namely interventional cardiology, critical care and licensing revenue. The interventional cardiology segment supplies the Group's proprietary drug-eluting stent products, coronary bare-metal stents, accompanying stent delivery balloon catheter systems, angioplasty balloons and catheters. The critical care segment supplies catheter systems and related accessories used during surgery and intensive care treatment and monitoring. The licensing revenue segment relates to payments and royalties associated with the licensing of the Group's proprietary drug-eluting stent technology and intellectual property.